Abstract P732: Genetic Ablation of Endothelial C3a-Receptor Confers Cerebrovascular Protection Independent of the Dynamics of Reperfusion in Stroke
Background: Stroke enhances endothelial C3a Receptor (C3aR End ) expression and humoral levels of C3a which is further exacerbated by intravenous thrombolysis (IVT). Therefore, it is critical to investigate the role of C3aR End in post-stroke neurovascular injury. Hypothesis: Genetic depletion of C3aR is vasculoprotective in stroke. Methods: Using a loxP - Cre approach (C3aR Flox/Flox xCdh5 Cre ), we generated mice conditionally deficient or sufficient in C3aR End (C3aR End-/- or C3aR End+/+ ), and subjected males (6±0.5-mo old) to thrombotic stroke (TS). Cerebral blood flow (CBF), behavioral outcomes, infarct volume, blood brain barrier (BBB) leakage, brain hemoglobin (Hb) content, brain tissue oxygen (PbtO 2 ) , neutrophil polarization ( Proinflammatory N1: Li6G + CD206 - vs. Antiinflammatory N2: Li6G + CD206 + ) and their brain infiltration were analyzed. P<0.05 was considered statistically significant. Results: TS resulted in similar degree of cerebral ischemia in both groups (N=10/gp); however, CBF, behavior, and infarct volume were significantly improved in C3aR End-/- vs. C3aR End+/+ mice at 72h post-TS. BBB-leakage and brain-Hb at 72h were less in C3aR End-/- vs. C3aR End+/+ mice but this did not meet significance (N=5/gp). Interestingly, C3a infusion 3h post-TS significantly enhanced BBB-leakage and brain-Hb in C3aR End+/+ but not in C3aR End-/- mice at 72h (N=5/gp), demonstrating that C3a in conjunction with C3aR End exacerbates neurovascular injury in TS. Moreover, late-IVT at 4h post-TS (2 mg/kgbwt; N=8/gp) significantly enhanced PbtO 2 in C3aR End-/- vs. C3aR End+/+ mice when assessed at 6h. Finally, C3aR deficiency significantly enhanced the N2/N1 ratio relative to the C3aR sufficient group at 24h post-TS (N=3/gp); thus inducing an anti-inflammatory effect and reduced neutrophil brain infiltration. Conclusion: C3aR End plays a critical role in stroke injury. Future studies targeting brain specific C3aR End are warranted.